1.Forster, P, Forster, L, Renfrew, C, Forster, M.Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Nat Acad Sci 2020;117:9241–9243.
3.Chen, N, Zhou, M, Dong, X, et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–513.
4.Guan, W-j, Ni, Z-y, Hu, Y, et al.Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–1720.
5.Wang, D, Hu, B, Hu, C, et al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–1069.
6.Han, R, Huang, L, Jiang, H, Dong, J, Peng, H, Zhang, D.Early clinical and CT manifestations of coronavirus disease 2019 (COVID-19) pneumonia. Am J Roentgenol 2020:1–6.
7.Huang, C, Wang, Y, Li, X, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
8.Bhatraju, PK, Ghassemieh, BJ, Nichols, M, et al.COVID-19 in critically ill patients in the Seattle region—case series. N Engl J Med 2020;382:2012–2022.
9.Grasselli, G, Zangrillo, A, Zanella, A, et al.Baseline characteristics and outcomes of 1,591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020;323:1574–1581.
10.Ruan, Q, Yang, K, Wang, W, Jiang, L, Song, J.Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46:846–848.
11.Young, BE, Ong, SWX, Kalimuddin, S, et al.Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020;323:1488–1494.
12.Richardson, S, Hirsch, JS, Narasimhan, M, et al.Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA 2020;323:2052–2059.
13.Tian, S, Hu, N, Lou, J, et al.Characteristics of COVID-19 infection in Beijing. J Infect 2020;80:401–406.
14.Yuan, J, Li, M, Lv, G, Lu, ZK.Monitoring transmissibility and mortality of COVID-19 in Europe. Int J Infect Dis 2020;95:311–315.
15.Basu, A.Estimating the infection fatality rate among symptomatic COVID-19 cases in the United States. Health Affairs 2020. doi: 10.1377/hlthaff.2020.00455.
16.Verity, R, Okell, LC, Dorigatti, I, et al.Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020;20:669–677.
17.Roncon, L, Zuin, M, Rigatelli, G, Zuliani, G.Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol 2020;127:104354.
18.Zhou, F, Yu, T, Du, R, et al.Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–1062.
19.Cariou, B, Hadjadj, S, Wargny, M, et al.Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 2020;63:1500–1515.
20.Zhang, P, Zhu, L, Cai, J, et al.Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 2020;126:1671–1681.
21.Vaduganathan, M, Vardeny, O, Michel, T, McMurray, JJV, Pfeffer, MA, Solomon, SD.Renin–angiotensin–aldosterone system inhibitors in patients with COVID-19. N Engl J Med 2020;382:1653–1659.
22.Brancatella, A, Ricci, D, Viola, N, Sgrò, D, Santini, F, Latrofa, F.Subacute thyroiditis after SARS-CoV-2 infection. J Clin Endocrinol Metab 2020;105(7):dgaa276.